ClinicalTrials.gov
public full text
Public Domain
Mirabegron For Erectile Dysfunction
The only class of oral erectile dysfunction (ED) medication on the market are the phosphodiesterase Type 5 inhibitors (PDE5i). This pilot study is being done to evaluate the effect of Mirabegron, an oral beta-3 adrenergic agonist, on men with both Overactive Bladder (OAB) symptoms and mild to moderate ED.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction#995341
- The Management of Erectile Dysfunction With Placebo Only#898900
- A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.#1163185
- Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females#890089
- Safety and Efficacy of Ohhmed Treatments for the Improvement of Erectile Dysfunction - A Feasibility Study#813909
Record · ID 878450
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive